Combined chemotherapy and differentiation therapy in the treatment of advanced non-small-cell lung cancer

Francesco Recchia, Gigliola Sica, Sandro De Filippis, Silvio Rea, Luigi Frati

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: In this phase-II pilot study a cisplatin-based treatment was combined with biological agents capable of inducing differentiation in non-small-cell lung cancer (NSCLC) cells with the aim of ameliorating response to chemotherapy. Patients and methods: Forty patients (PTS) with inoperable stage III-B or IV NSCLC were treated with cisplatin (CDDP) 24 mg/m2 on days 1 to 5, 5-fluorouracil (5-FU) 500 mg/m2, by continuous infusion on days 1 to 5 and vindesine (VDS) 3 mg/m2 on days 1 and 5. Beta-interferon (β-IFN) 1 x 106 IU/m2 subcutaneously 3 times a week and retinyl palmitate (R) 50,000 IU orally BID were administered between chemotherapy cycles. Responders were maintained with the same dose β-IFN plus R 15,000 IU BID. Half of the PTS had an ECOG performance status of 0-1, 62% of tumours were of squamous histology and 77.5% of PTS had stage IV disease. A median of four courses of chemotherapy per PT was delivered. Results: Forty PTS were evaluable. Seventeen PTS responded, (RR 42%, 95% C.I. 27%-57%). Of the 17 responders 13 had squamous histology. The median response duration was 5.1 months. The median overall survival was 9.1 months. Gastrointestinal toxicity occurred in 58% of PTS, anaemia in 20%, leukopenia in 30%. Conclusions: The association of CDDP, VDS, 5-FU, β-IFN and R shows activity in NSCLC, particularly in tumours with squamous histology, with a substantial toxicity.

Original languageEnglish
Pages (from-to)3761-3765
Number of pages5
JournalAnticancer Research
Volume17
Issue number5 B
Publication statusPublished - Sep 1997

Fingerprint

Non-Small Cell Lung Carcinoma
Drug Therapy
Vindesine
Histology
Fluorouracil
Cisplatin
Therapeutics
Interferon-beta
Leukopenia
Biological Factors
Anemia
Neoplasms
Survival

Keywords

  • Beta-interferon
  • Chemotherapy
  • Non-small-cell lung cancer
  • Retinyl palmitate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Combined chemotherapy and differentiation therapy in the treatment of advanced non-small-cell lung cancer. / Recchia, Francesco; Sica, Gigliola; De Filippis, Sandro; Rea, Silvio; Frati, Luigi.

In: Anticancer Research, Vol. 17, No. 5 B, 09.1997, p. 3761-3765.

Research output: Contribution to journalArticle

Recchia, Francesco ; Sica, Gigliola ; De Filippis, Sandro ; Rea, Silvio ; Frati, Luigi. / Combined chemotherapy and differentiation therapy in the treatment of advanced non-small-cell lung cancer. In: Anticancer Research. 1997 ; Vol. 17, No. 5 B. pp. 3761-3765.
@article{7ea6eb59b8124ff8a0beb4f62863b1ee,
title = "Combined chemotherapy and differentiation therapy in the treatment of advanced non-small-cell lung cancer",
abstract = "Background: In this phase-II pilot study a cisplatin-based treatment was combined with biological agents capable of inducing differentiation in non-small-cell lung cancer (NSCLC) cells with the aim of ameliorating response to chemotherapy. Patients and methods: Forty patients (PTS) with inoperable stage III-B or IV NSCLC were treated with cisplatin (CDDP) 24 mg/m2 on days 1 to 5, 5-fluorouracil (5-FU) 500 mg/m2, by continuous infusion on days 1 to 5 and vindesine (VDS) 3 mg/m2 on days 1 and 5. Beta-interferon (β-IFN) 1 x 106 IU/m2 subcutaneously 3 times a week and retinyl palmitate (R) 50,000 IU orally BID were administered between chemotherapy cycles. Responders were maintained with the same dose β-IFN plus R 15,000 IU BID. Half of the PTS had an ECOG performance status of 0-1, 62{\%} of tumours were of squamous histology and 77.5{\%} of PTS had stage IV disease. A median of four courses of chemotherapy per PT was delivered. Results: Forty PTS were evaluable. Seventeen PTS responded, (RR 42{\%}, 95{\%} C.I. 27{\%}-57{\%}). Of the 17 responders 13 had squamous histology. The median response duration was 5.1 months. The median overall survival was 9.1 months. Gastrointestinal toxicity occurred in 58{\%} of PTS, anaemia in 20{\%}, leukopenia in 30{\%}. Conclusions: The association of CDDP, VDS, 5-FU, β-IFN and R shows activity in NSCLC, particularly in tumours with squamous histology, with a substantial toxicity.",
keywords = "Beta-interferon, Chemotherapy, Non-small-cell lung cancer, Retinyl palmitate",
author = "Francesco Recchia and Gigliola Sica and {De Filippis}, Sandro and Silvio Rea and Luigi Frati",
year = "1997",
month = "9",
language = "English",
volume = "17",
pages = "3761--3765",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5 B",

}

TY - JOUR

T1 - Combined chemotherapy and differentiation therapy in the treatment of advanced non-small-cell lung cancer

AU - Recchia, Francesco

AU - Sica, Gigliola

AU - De Filippis, Sandro

AU - Rea, Silvio

AU - Frati, Luigi

PY - 1997/9

Y1 - 1997/9

N2 - Background: In this phase-II pilot study a cisplatin-based treatment was combined with biological agents capable of inducing differentiation in non-small-cell lung cancer (NSCLC) cells with the aim of ameliorating response to chemotherapy. Patients and methods: Forty patients (PTS) with inoperable stage III-B or IV NSCLC were treated with cisplatin (CDDP) 24 mg/m2 on days 1 to 5, 5-fluorouracil (5-FU) 500 mg/m2, by continuous infusion on days 1 to 5 and vindesine (VDS) 3 mg/m2 on days 1 and 5. Beta-interferon (β-IFN) 1 x 106 IU/m2 subcutaneously 3 times a week and retinyl palmitate (R) 50,000 IU orally BID were administered between chemotherapy cycles. Responders were maintained with the same dose β-IFN plus R 15,000 IU BID. Half of the PTS had an ECOG performance status of 0-1, 62% of tumours were of squamous histology and 77.5% of PTS had stage IV disease. A median of four courses of chemotherapy per PT was delivered. Results: Forty PTS were evaluable. Seventeen PTS responded, (RR 42%, 95% C.I. 27%-57%). Of the 17 responders 13 had squamous histology. The median response duration was 5.1 months. The median overall survival was 9.1 months. Gastrointestinal toxicity occurred in 58% of PTS, anaemia in 20%, leukopenia in 30%. Conclusions: The association of CDDP, VDS, 5-FU, β-IFN and R shows activity in NSCLC, particularly in tumours with squamous histology, with a substantial toxicity.

AB - Background: In this phase-II pilot study a cisplatin-based treatment was combined with biological agents capable of inducing differentiation in non-small-cell lung cancer (NSCLC) cells with the aim of ameliorating response to chemotherapy. Patients and methods: Forty patients (PTS) with inoperable stage III-B or IV NSCLC were treated with cisplatin (CDDP) 24 mg/m2 on days 1 to 5, 5-fluorouracil (5-FU) 500 mg/m2, by continuous infusion on days 1 to 5 and vindesine (VDS) 3 mg/m2 on days 1 and 5. Beta-interferon (β-IFN) 1 x 106 IU/m2 subcutaneously 3 times a week and retinyl palmitate (R) 50,000 IU orally BID were administered between chemotherapy cycles. Responders were maintained with the same dose β-IFN plus R 15,000 IU BID. Half of the PTS had an ECOG performance status of 0-1, 62% of tumours were of squamous histology and 77.5% of PTS had stage IV disease. A median of four courses of chemotherapy per PT was delivered. Results: Forty PTS were evaluable. Seventeen PTS responded, (RR 42%, 95% C.I. 27%-57%). Of the 17 responders 13 had squamous histology. The median response duration was 5.1 months. The median overall survival was 9.1 months. Gastrointestinal toxicity occurred in 58% of PTS, anaemia in 20%, leukopenia in 30%. Conclusions: The association of CDDP, VDS, 5-FU, β-IFN and R shows activity in NSCLC, particularly in tumours with squamous histology, with a substantial toxicity.

KW - Beta-interferon

KW - Chemotherapy

KW - Non-small-cell lung cancer

KW - Retinyl palmitate

UR - http://www.scopus.com/inward/record.url?scp=0031441115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031441115&partnerID=8YFLogxK

M3 - Article

C2 - 9427776

AN - SCOPUS:0031441115

VL - 17

SP - 3761

EP - 3765

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5 B

ER -